Abstract
DCZ3301, a novel aryl-guanidino compound previously reported by our group, exerts cytotoxic effects against multiple myeloma (MM), diffused large B cell lymphoma (DLBCL), and T-cell leukemia/lymphoma. However, the underlying mechanism of its action remains unknown. We generated bortezomib (BTZ)-resistant cell lines, treated them with various concentrations of DCZ3301 over varying periods, and studied its effect on colony formation, cell proliferation, apoptosis, cell cycle, DNA synthesis, and DNA damage response. We validated our results using in vitro and in vivo experimental models. DCZ3301 overcame bortezomib (BTZ) resistance through regulation of the G2/M checkpoint in multiple myeloma (MM) in vitro and in vivo. Furthermore, treatment of BTZ-resistant cells with DCZ3301 restored their drug sensitivity. DCZ3301 induced M phase cell cycle arrest in MM mainly via inhibiting DNA repair and enhancing DNA damage. Moreover, DCZ3301 promoted the phosphorylation of ATM, ATR, and their downstream proteins, and these responses were blocked by the ATM specific inhibitor KU55933. Our study provides a proof-of-concept that warrants the clinical evaluation of DCZ3301 as a novel anti-tumor compound against BTZ resistance in MM.
References
Jul 12, 2002·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Clare H McGowan
Jan 31, 2003·Nature·Jiri Bartek, Jiri Lukas
Jun 19, 2003·Journal of the National Cancer Institute·Renee Twombly
Apr 13, 2004·Oncogene·Maria CastedoGuido Kroemer
Feb 21, 2006·Current Opinion in Cell Biology·Rose BoutrosBernard Ducommun
Sep 14, 2006·Pharmacological Reviews·Ting-Chao Chou
Oct 20, 2006·Nature·Shideng BaoJeremy N Rich
Dec 25, 2007·Cell Research·Meena ShrivastavJac A Nickoloff
Jan 31, 2008·British Journal of Cancer·N Bucher, C D Britten
Dec 19, 2008·Nature·Andrew XiaoC David Allis
Jan 14, 2010·Cancer Research·Ting-Chao Chou
Jan 21, 2010·The Oncologist·Heinz LudwigSonja Zweegman
Aug 19, 2010·Journal of Cellular and Molecular Medicine·Angela PoehlmannRegine Schneider-Stock
Nov 3, 2010·Advances in Cancer Research·Joanne SmithDavid A Gillespie
Mar 25, 2011·Molecular Cancer Therapeutics·Kin Fan OnRandy Y C Poon
Apr 30, 2011·Nature Reviews. Molecular Cell Biology·Ilio VitaleGuido Kroemer
May 14, 2011·Leukemia·D K WaltersD F Jelinek
Aug 13, 2013·PloS One·Christine VignonOlivier Herault
Nov 12, 2013·Molecular Cell·Maikel Castellano-PozoAndrés Aguilera
Aug 12, 2014·Biochemical Society Transactions·Megan Y MurrayKristian M Bowles
May 31, 2015·Carcinogenesis·Wen-Cheng ChouChen-Yang Shen
Jan 23, 2016·Cellular and Molecular Life Sciences : CMLS·Sonja Matt, Thomas G Hofmann
Feb 3, 2016·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Tatiana V DenisenkoBoris Zhivotovsky
Mar 24, 2016·Oncotarget·Minjie GaoJumei Shi
Dec 3, 2016·Haematologica·Hans Erik JohnsenKaren Dybkær
Jan 6, 2017·Oncotarget·Juan J GuFrancisco J Hernandez-Ilizaliturri
Oct 1, 2017·DNA Repair·Elena PiresClaudia Wiese
Oct 13, 2017·Cell Death & Disease·Xi SunWeiliang Zhu
Nov 8, 2017·Theranostics·Minjie GaoJumei Shi
Nov 25, 2017·Science·Lilian KabecheLee Zou
Apr 25, 2018·Acta Biochimica Et Biophysica Sinica·Wenqin XiaoWeiliang Zhu
Jun 9, 2018·International Journal of Molecular Sciences·Dauren AlimbetovDavid Kipling
Jun 29, 2018·Anti-cancer Drugs·Ni ZhenMin Xu
Sep 25, 2018·Cancer Treatment Reviews·Pawel RobakTadeusz Robak
Feb 28, 2019·Theranostics·Ni ZhenQiuhui Pan
Aug 20, 2019·ELife·Olga AfonsoHelder Maiato